Format

Send to

Choose Destination
Cancer Radiother. 2013 Jun;17(3):183-90. doi: 10.1016/j.canrad.2012.12.006. Epub 2013 Mar 15.

[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].

[Article in French]

Author information

1
Département de radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France. julian.jacob28@gmail.com

Abstract

PURPOSE:

Prospective monocentric study of the toxicities related to concurrent administration of trastuzumab to breast radiotherapy.

PATIENTS AND METHODS:

One hundred and seventy-three patients were treated between June 2003 and March 2009 by concurrent trastuzumab with normofractionated radiotherapy. Trastuzumab was delivered every 3 weeks (8mg/kg in the first infusion then 6mg/kg) during a median time of 12 months (2-62). Left ventricular ejection fraction was assessed by echocardiography or cardiac scintigraphy at baseline, before and after radiotherapy, every 3 months for 1 year and annually. A left ventricular ejection fraction strictly lower than 55% was considered as altered. All toxicities were evaluated using Common Terminology Criteria for Adverse Effects version 3.0.

RESULTS:

Median follow-up was 52 months (17-88). Median age was 52 years (25-83). One hundred and thirty-four patients (77.5%) received radiotherapy to the internal mammary chain. Acute grade 1, 2 and 3 epithelitis was described in 132 (76.3%), 32 (18.5%) and six patients (3.4%), respectively. At 23 months, grade 1 and 2 fibrosis was observed in 31 and eight patients, respectively (18.8 and 4.6%). Left ventricular ejection fraction remained normal for 159 patients (91.9%) before radiotherapy. Among them, 18 (11.3%) experienced a left ventricular ejection fraction alteration, eight (5.0%) at the completion of radiotherapy. Congestive heart failure occurred in one patient (0.6%).

CONCLUSIONS:

Toxicities related to the association of trastuzumab to breast radiotherapy were mild. Further follow-up is warranted.

PMID:
23499212
DOI:
10.1016/j.canrad.2012.12.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center